|
Market Closed -
London S.E.
19:35:16 28/08/2026 +04
|
5-day change | 1st Jan Change | ||
| 11,970.00 GBX | -1.19% |
|
-2.21% | -13.20% |
| 08-28 | AstraZeneca PLC : Jefferies reaffirms its Buy rating | ZD |
| 08-28 | Astrazeneca Demonstrates Positive Phase Iii Results for Tezspire in Eosinophilic Esophagitis | CI |
Company Valuation: AstraZeneca PLC
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 182,034 | 209,442 | 209,268 | 203,171 | 287,813 | 251,732 | - | - |
| Change | - | 15.06% | -0.08% | -2.91% | 41.66% | -12.54% | - | - |
| Enterprise Value (EV) 1 | 206,417 | 232,365 | 231,778 | 227,741 | 311,187 | 271,058 | 263,384 | 254,878 |
| Change | - | 12.57% | -0.25% | -1.74% | 36.64% | -12.9% | -2.83% | -3.23% |
| P/E | 1,469x | 64.1x | 35.4x | 29.1x | 28.4x | 20.9x | 18.3x | 15.9x |
| PBR | 4.24x | 5.65x | 5.39x | 5.02x | 5.96x | 4.67x | 4.14x | 3.52x |
| PEG | - | 0x | 0.4x | 1.6x | 0.6x | 1.1x | 1.3x | 1.1x |
| Capitalization / Revenue | 4.87x | 4.72x | 4.57x | 3.76x | 4.9x | 3.98x | 3.77x | 3.53x |
| EV / Revenue | 5.52x | 5.24x | 5.06x | 4.21x | 5.3x | 4.29x | 3.94x | 3.58x |
| EV / EBITDA | 27.2x | 25.2x | 17.1x | 13.6x | 16x | 12.2x | 10.8x | 9.53x |
| EV / EBIT | 20.8x | 17.4x | 15.9x | 13.5x | 16.8x | 12.9x | 11.3x | 9.97x |
| EV / FCF | 42.4x | 26.7x | 25.8x | 22.9x | 26.5x | 28.8x | 20.2x | 17.3x |
| FCF Yield | 2.36% | 3.75% | 3.88% | 4.36% | 3.78% | 3.47% | 4.96% | 5.77% |
| Dividend per Share 2 | 2.87 | 2.9 | 2.9 | 3.1 | 3.2 | 3.339 | 3.561 | 3.662 |
| Rate of return | 2.44% | 2.15% | 2.15% | 2.37% | 1.72% | 2.06% | 2.19% | 2.26% |
| EPS 2 | 0.08 | 2.11 | 3.81 | 4.5 | 6.54 | 7.774 | 8.89 | 10.2 |
| Distribution rate | 3,588% | 137% | 76.1% | 68.9% | 48.9% | 43% | 40.1% | 35.9% |
| Net sales 1 | 37,417 | 44,351 | 45,811 | 54,073 | 58,739 | 63,250 | 66,839 | 71,275 |
| EBITDA 1 | 7,586 | 9,237 | 13,580 | 16,691 | 19,476 | 22,145 | 24,280 | 26,739 |
| EBIT 1 | 9,928 | 13,350 | 14,534 | 16,928 | 18,478 | 21,047 | 23,260 | 25,557 |
| Net income 1 | 112 | 3,288 | 5,961 | 7,035 | 10,225 | 12,022 | 13,610 | 15,489 |
| Net Debt 1 | 24,383 | 22,923 | 22,510 | 24,570 | 23,374 | 19,326 | 11,652 | 3,145 |
| Reference price 2 | 117.51 | 135.16 | 135.02 | 131.05 | 185.60 | 162.30 | 162.30 | 162.30 |
| Nbr of stocks (in thousands) | 1,549,159 | 1,549,528 | 1,549,926 | 1,550,317 | 1,550,726 | 1,551,024 | - | - |
| Announcement Date | 10/02/22 | 09/02/23 | 08/02/24 | 06/02/25 | 10/02/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 20.88x | 4.29x | 12.24x | 2.06% | 252B | |
| 33.44x | 12.14x | 24.6x | 0.59% | 1,047B | |
| 29.82x | - | - | 2% | 646B | |
| 32.61x | 7.57x | 15.74x | 2.68% | 451B | |
| 19.99x | 4.75x | 11.76x | 2.79% | 355B | |
| 21.76x | 5.62x | 13.93x | 2.85% | 291B | |
| 27.35x | 7.07x | 12.56x | 2.33% | 234B | |
| 13.25x | 4.77x | 9.95x | 3.83% | 203B | |
| -44.51x | 6.43x | 25.11x | 2.26% | 181B | |
| 17.52x | 3.32x | 8.48x | 6.16% | 159B | |
| Average | 17.21x | 6.22x | 14.93x | 2.76% | 381.86B | |
| Weighted average by Cap. | 23.96x | 7.83x | 17.34x | 2.14% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- AZN Stock
- Valuation AstraZeneca PLC
Select your edition
All financial news and data tailored to specific country editions
